In Vitro Diagnostics Market
The in vitro diagnostics market is undergoing structural transformation, shifting from centralized laboratory testing to decentralized point-of-care platforms. Valued at $96.5 billion in 2026 and forecast to reach $140.4 billion by 2033 at 5.5% CAGR, the market is increasingly driven by molecular diagnostics, software-driven interpretation, and recurring reagent revenue rather than instrument sales. Early movers securing decentralized placement and broad assay menus are establishing competitive advantages, while health systems must treat platform selection as strategic commitments rather than procurement events.